DexCom, Inc. (DXCM) – What Are Brokerages Saying About This Stock?

Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned a consensus recommendation of “Buy” from the twenty-eight brokerages that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, twenty-four have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $95.50.

A number of research analysts recently issued reports on the company. Benchmark lifted their target price on DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, July 31st. UBS Group upped their price target on shares of DexCom from $102.00 to $107.00 and gave the company a “buy” rating in a report on Friday, October 30th. JPMorgan Chase & Co. raised their price objective on shares of DexCom from $82.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 30th. Argus lifted their price objective on shares of DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, Barclays boosted their target price on shares of DexCom from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, October 30th.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $83.33 on Friday. The stock has a fifty day moving average price of $84.30 and a two-hundred day moving average price of $75.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.40 and a current ratio of 1.74. The firm has a market cap of $31.08 billion, a P/E ratio of 32.68, a PEG ratio of 1.34 and a beta of 1.45. DexCom has a 1 year low of $56.72 and a 1 year high of $92.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. The company had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.61 EPS. Research analysts forecast that DexCom will post 2.68 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $78.62, for a total value of $201,660.30. Following the transaction, the executive vice president owned 120,913 shares in the company, valued at approximately $9,506,180.06. The trade was a 2.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total value of $145,316.00. Following the completion of the transaction, the executive vice president directly owned 98,185 shares in the company, valued at $8,392,853.80. This represents a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 22,822 shares of company stock valued at $1,920,193. 0.28% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On DexCom

Institutional investors and hedge funds have recently modified their holdings of the stock. Mather Group LLC. grew its position in shares of DexCom by 27.7% in the 3rd quarter. Mather Group LLC. now owns 563 shares of the medical device company’s stock valued at $49,000 after acquiring an additional 122 shares during the period. Fifth Third Wealth Advisors LLC lifted its stake in DexCom by 2.8% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 5,510 shares of the medical device company’s stock valued at $475,000 after purchasing an additional 150 shares during the last quarter. Elevation Wealth Partners LLC grew its holdings in DexCom by 61.0% during the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after purchasing an additional 152 shares during the period. MassMutual Private Wealth & Trust FSB grew its holdings in DexCom by 15.4% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after purchasing an additional 153 shares during the period. Finally, Simplicity Wealth LLC grew its holdings in DexCom by 5.4% during the third quarter. Simplicity Wealth LLC now owns 3,169 shares of the medical device company’s stock worth $273,000 after purchasing an additional 162 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.